GU Cancers 2019 | RANGE: ramucirumab plus docetaxel for urothelial cancer

Jeanny Aragon-Ching

Jeanny Aragon-Ching, MD, FACP, of the Inova Schar Cancer Institute, Fairfax, VA, discusses the results from the RANGE study (NCT02426125) of ramucirumab plus docetaxel in advanced or metastatic urothelial cancers. This interview was recorded at the 2019 Genitourinary Cancers Symposium, held in San Francisco, CA.

Share this video